PARC
An international phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults.
Bone Cancers (Ewing Sarcoma/Osteosarcoma), Brain and other Central Nervous System (CNS) Tumours, Leukaemia, Neuroblastoma
The PARC clinical trial is testing a new treatment for neuroblastoma, sarcoma, high grade glioma, and leukaemia in children and young adults. This study will be analysing a completely new treatment approach using a drug called BCT-100. Research has shown that a nutrient called ‘arginine’ is important in the survival of cancer cells. BCT-100 is a drug which can deplete arginine levels and starve the cancer cells. This trial will test if the drug is effective against specific types of cancer that have come back (relapsed) or not responded to previous treatment (refractory).
Disease Stage: Relapsed/refractory
Patient Age Range: 1- <25 years old
Sample Size: Up to 64 patients
Trial Sponsors:
- International: University of Birmingham
- National: ANZCHOG
